Literature DB >> 23318260

Chd5 requires PHD-mediated histone 3 binding for tumor suppression.

Shilpi Paul1, Alex Kuo, Thomas Schalch, Hannes Vogel, Leemor Joshua-Tor, W Richard McCombie, Or Gozani, Molly Hammell, Alea A Mills.   

Abstract

Chromodomain Helicase DNA binding protein 5 (CHD5) is a tumor suppressor mapping to 1p36, a genomic region that is frequently deleted in human cancer. Although CHD5 belongs to the CHD family of chromatin-remodeling proteins, whether its tumor-suppressive role involves an interaction with chromatin is unknown. Here we report that Chd5 binds the unmodified N terminus of H3 through its tandem plant homeodomains (PHDs). Genome-wide chromatin immunoprecipitation studies reveal preferential binding of Chd5 to loci lacking the active mark H3K4me3 and also identify Chd5 targets implicated in cancer. Chd5 mutations that abrogate H3 binding are unable to inhibit proliferation or transcriptionally modulate target genes, which leads to tumorigenesis in vivo. Unlike wild-type Chd5, Chd5-PHD mutants are unable to induce differentiation or efficiently suppress the growth of human neuroblastoma in vivo. Our work defines Chd5 as an N-terminally unmodified H3-binding protein and provides functional evidence that this interaction orchestrates chromatin-mediated transcriptional programs critical for tumor suppression.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23318260      PMCID: PMC3575599          DOI: 10.1016/j.celrep.2012.12.009

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  64 in total

1.  Suppression of tumorigenesis by the p53 target PUMA.

Authors:  Michael T Hemann; Jack T Zilfou; Zhen Zhao; Darren J Burgess; Gregory J Hannon; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-10       Impact factor: 11.205

Review 2.  Assays for the determination of structure and dynamics of the interaction of the chromodomain with histone peptides.

Authors:  Steven A Jacobs; Wolfgang Fischle; Sepideh Khorasanizadeh
Journal:  Methods Enzymol       Date:  2004       Impact factor: 1.600

3.  Structure of the HP1 chromodomain bound to histone H3 methylated at lysine 9.

Authors:  Peter R Nielsen; Daniel Nietlispach; Helen R Mott; Juliana Callaghan; Andrew Bannister; Tony Kouzarides; Alexey G Murzin; Natalia V Murzina; Ernest D Laue
Journal:  Nature       Date:  2002-02-20       Impact factor: 49.962

4.  The dMi-2 chromodomains are DNA binding modules important for ATP-dependent nucleosome mobilization.

Authors:  Karim Bouazoune; Angelika Mitterweger; Gernot Längst; Axel Imhof; Asifa Akhtar; Peter B Becker; Alexander Brehm
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

5.  CHD5, a tumor suppressor that is epigenetically silenced in lung cancer.

Authors:  Rui Zhao; Qitao Yan; Jingye Lv; Haili Huang; Wenling Zheng; Bao Zhang; Wenli Ma
Journal:  Lung Cancer       Date:  2011-12-18       Impact factor: 5.705

6.  Structure of HP1 chromodomain bound to a lysine 9-methylated histone H3 tail.

Authors:  Steven A Jacobs; Sepideh Khorasanizadeh
Journal:  Science       Date:  2002-02-21       Impact factor: 47.728

7.  A three-gene expression signature model for risk stratification of patients with neuroblastoma.

Authors:  Idoia Garcia; Gemma Mayol; José Ríos; Gema Domenech; Nai-Kong V Cheung; André Oberthuer; Matthias Fischer; John M Maris; Garrett M Brodeur; Barbara Hero; Eva Rodríguez; Mariona Suñol; Patricia Galvan; Carmen de Torres; Jaume Mora; Cinzia Lavarino
Journal:  Clin Cancer Res       Date:  2012-02-10       Impact factor: 12.531

8.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

Authors:  J D Dignam; R M Lebovitz; R G Roeder
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

9.  Lack of interstitial chromosome 1p deletions in clinically-detected neuroblastoma.

Authors:  M B Godfried; M Veenstra; A Valent; P v Sluis; P A Voûte; R Versteeg; H N Caron
Journal:  Eur J Cancer       Date:  2002-07       Impact factor: 9.162

10.  Decreased expression of chromodomain helicase DNA-binding protein 5 is an unfavorable prognostic marker in patients with primary gallbladder carcinoma.

Authors:  Xilin Du; Tao Wu; Jianguo Lu; Li Zang; Nuan Song; Tao Yang; Huadong Zhao; Shengzhi Wang
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

View more
  27 in total

1.  The tumor suppressor Chd5 is induced during neuronal differentiation in the developing mouse brain.

Authors:  Assaf Vestin; Alea A Mills
Journal:  Gene Expr Patterns       Date:  2013-10-09       Impact factor: 1.224

Review 2.  Architects of the genome: CHD dysfunction in cancer, developmental disorders and neurological syndromes.

Authors:  Wangzhi Li; Alea A Mills
Journal:  Epigenomics       Date:  2014       Impact factor: 4.778

3.  The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex.

Authors:  Venkatadri Kolla; Koumudi Naraparaju; Tiangang Zhuang; Mayumi Higashi; Sriharsha Kolla; Gerd A Blobel; Garrett M Brodeur
Journal:  Biochem J       Date:  2015-06-01       Impact factor: 3.857

Review 4.  The Chromodomain Helicase DNA-Binding Chromatin Remodelers: Family Traits that Protect from and Promote Cancer.

Authors:  Alea A Mills
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

Review 5.  Role of CHD5 in human cancers: 10 years later.

Authors:  Venkatadri Kolla; Tiangang Zhuang; Mayumi Higashi; Koumudi Naraparaju; Garrett M Brodeur
Journal:  Cancer Res       Date:  2014-01-13       Impact factor: 12.701

6.  The tumor suppressor chromodomain helicase DNA-binding protein 5 (CHD5) remodels nucleosomes by unwrapping.

Authors:  Jinhua Quan; Timur Yusufzai
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

7.  Chd5 orchestrates chromatin remodelling during sperm development.

Authors:  Wangzhi Li; Jie Wu; Sang-Yong Kim; Ming Zhao; Stephen A Hearn; Michael Q Zhang; Marvin L Meistrich; Alea A Mills
Journal:  Nat Commun       Date:  2014-05-13       Impact factor: 14.919

Review 8.  Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas.

Authors:  Crystal S Seldon; Lauren E Colbert; William A Hall; Sarah B Fisher; David S Yu; Jerome C Landry
Journal:  World J Gastrointest Oncol       Date:  2016-04-15

Review 9.  Epigenetic inheritance: histone bookmarks across generations.

Authors:  Eric I Campos; James M Stafford; Danny Reinberg
Journal:  Trends Cell Biol       Date:  2014-09-18       Impact factor: 20.808

Review 10.  ATP-dependent chromatin remodeling complexes as novel targets for cancer therapy.

Authors:  Kimberly Mayes; Zhijun Qiu; Aiman Alhazmi; Joseph W Landry
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.